Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma".

A.M Evens,I Helenowski,J Kolesar,B Jovanovic,K.R Carson,S.A Gregory,C Nabhan,P.F Caimi,N Islam,L.I Gordon,P.M Barr

doi:10.1093/annonc/mdu179

Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma".

A.M Evens, I Helenowski + Show 9 more

Open Access

https://doi.org/10.1093/annonc/mdu179

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 20, 2013
License type: publisher-specific-oa

Affiliation: University of Massachusetts Chan Medical School, UW Carbone Cancer Center, Northwestern University, Advocate Lutheran General Hospital

#High-risk Burkitt's Lymphoma #Untreated Burkitt's Lymphoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background Despite improvement with intensive multi-agent chemotherapy, 2-year progression-free survival (PFS) rates for adults with high-risk Burkitt's lymphoma (BL) remains <55%.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.